Transdermal Drug Delivery systems from ProSolus, Inc. are created for multiple therapeutic categories. We formulate and develop AB-rated Generics, 505(b)(2) and OTC products… all with the ProSolus stamp of optimal delivery technology.

We endeavor to execute agreements with pharmaceutical marketing companies seeking to develop and commercialize TDDs. We evaluate FDA approved transdermal formulations to be in-license and/or develop internally. Once engaged, we work with our partners to complete the requirements for clinical development and FDA approval. For more information about putting a ProSolus Partnership to work for you, please contact us.